GUARDANT HEALTH INC

Guardant Health’s directors buy ~4k shares each, boosting holdings while the biotech firm remains a key player in cancer diagnostics – see the latest share‑ownership updates.

Guardant Health insider sales spark debate: are executives selling shares amid a shaky P/E and fierce competition, or is it routine portfolio management?

Guardant Health’s insider sales and Evercore’s lowered price target signal changing investor confidence; explore how these SEC filings and market shifts affect the biotech stock’s future.

Guardant Health insider sale sparks volatility concerns: negative P/E, shaky growth, and strategic recalibration needed for investors to assess sustainability.

Guardant Health expands its liquid‑biopsy Reveal test to monitor late‑stage cancer therapy and launches a global consortium to standardize exabyte‑scale data for AI‑driven oncology research.

Guardant Health raises $650 M with upsized convertible notes and a public equity deal, fueling precision‑oncology expansion while sparking concerns over debt and dilution.

Guardant Health reports a 39 % Q3 revenue jump, raises FY 2025 outlook to $965‑$970 M, and sees a 26 % pre‑market lift as investors back its precision oncology growth.

Guardant Health Inc. reports a 31% increase in revenue for Q2 2025, exceeding analyst estimates and positioning the biotechnology company for continued success in the rapidly evolving field of cancer diagnostics.

Guardant Health Inc. has announced financial updates and strategic partnerships, including a new awareness campaign for colorectal cancer screening, as the company continues to evolve and adapt in the biotechnology and healthcare sectors.

Guardant Health Inc is thriving in the competitive biotechnology sector, with a projected earnings turnaround, strategic partnerships, and leadership changes positioning the company for continued growth and impact.